Hims & Hers shares rise as company adds new weight-loss medications to platform

The Hims app arranged on a smartphone in New York on Feb. 12, 2025. Hims & Hers Health shares rose more than 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, through its platform. Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late ...